NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE Drug Patent Profile

When do Naloxone Hydrochloride And Pentazocine Hydrochloride patents expire, and when can generic versions of Naloxone Hydrochloride And Pentazocine Hydrochloride launch?

Naloxone Hydrochloride And Pentazocine Hydrochloride is a drug marketed by Lupin, Sun Pharm Inds Ltd, and Watson Labs. and is included in three NDAs.

The generic ingredient in NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is naloxone hydrochloride; pentazocine hydrochloride. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride; pentazocine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naloxone Hydrochloride And Pentazocine Hydrochloride

A generic version of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE was approved as naloxone hydrochloride; pentazocine hydrochloride by WATSON LABS on January 21^st, 1997.

Summary for NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	3
Clinical Trials:	2
DailyMed Link:	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1
Office of Research on Women's Health (ORWH)	Phase 1
National Center for Complementary and Integrative Health (NCCIH)	Phase 1

See all NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE clinical trials

Pharmacology for NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

Drug Class	Opioid Antagonist Partial Opioid Agonist/Antagonist
Mechanism of Action	Competitive Opioid Antagonists Opioid Antagonists Partial Opioid Agonists

US Patents and Regulatory Information for NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	075735-001	Jul 11, 2001	AB	RX	No	No
Sun Pharm Inds Ltd	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	075523-001	Mar 17, 2000	AB	RX	No	No
Watson Labs	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	074736-001	Jan 21, 1997	AB	RX	No	Yes

Market Dynamics and Financial Trajectory for Naloxone Hydrochloride and Pentazocine Hydrochloride

Last updated: March 2, 2026

What Are the Market Fundamentals for Naloxone Hydrochloride and Pentazocine Hydrochloride?

Naloxone Hydrochloride is an opioid antagonist primarily used in reversing opioid overdoses. Pentazocine Hydrochloride is a semi-synthetic opioid analgesic used in pain management. Both drugs operate within distinct segments of the opioid treatment landscape.

Market Size and Growth Trends

Drug	2022 Global Market Size	CAGR (2023-2028)	Key Drivers
Naloxone	~$1.2 billion[1]	8%	Increase in opioid overdose deaths, expanding distribution channels, regulatory approvals for multiple delivery forms
Pentazocine	~$150 million[2]	4.5%	Persistent demand for pain management, regulations favoring non-injectable formulations, competitor activity

The total market for opioid overdose reversal agents is forecasted to surpass $2 billion by 2028, driven by rising overdose deaths. The demand for naloxone particularly benefits from increased public health initiatives and wider availability through pharmacies and community programs. The pentazocine market remains more localized, with growth constrained by regulatory and prescriber preferences favoring other opioid analgesics.

What Factors Drive Market Dynamics?

Regulatory Environment

• Naloxone: Expanded FDA approvals for overdoses, including auto-injectors and nasal sprays. Laws in the US and EU allow over-the-counter sales, increasing accessibility.
• Pentazocine: Stringent regulations limit usage to prescription settings. Some jurisdictions restrict its prescribing due to abuse potential.

Market Penetration and Distribution

• Naloxone: Distribution through public health agencies, pharmacies, and harm reduction programs. The availability of low-cost formulations accelerates uptake.
• Pentazocine: Prescribed mainly in hospital settings or specialized pain clinics. Limited further distribution pathways.

Competitive Landscape

• Naloxone: Dominated by Mylan (now part of Viatris), Teva, and Emergent BioSolutions. The market exhibits innovation in delivery systems, with competitors launching novel devices.
• Pentazocine: Competition exists but is limited, with generic manufacturers and less market diversity. Proprietary formulations are fewer.

Patent and Pricing Dynamics

• Naloxone: Many formulations are off-patent, leading to price erosion but broad adoption. Some new formulations remain under patent, maintaining premium pricing.
• Pentazocine: Generic prevalence suppresses pricing, with typical costs around $10–$20 per dose.

Market Barriers

• Naloxone: Cold chain logistics for certain formulations, stigma associated with opioid-related products, and legal barriers in some regions.
• Pentazocine: Concerns over misuse potential and restrictions on prescribing.

What Are the Financial Trajectories and Investment Outlooks?

Revenue Projections

Drug	2023 Revenue	2028 Projection	Key Factors Affecting Revenue
Naloxone	~$1.3 billion	~$2.2 billion	Expanded OTC availability, new formulations
Pentazocine	~$150 million	~$180 million	Ongoing demand in pharmacological research, stabilized growth

Naloxone: The revenue growth rate averages 8% annually, driven by increased overdose incidences and expanded access. Price stabilization due to generic competition moderates margins.

Pentazocine: Growth rates are slower, at 4.5%, with revenues plateauing as prescriber preferences shift towards other analgesics or multimodal pain therapy.

Investment and R&D Trends

• Naloxone: Investment in long-acting formulations, auto-injectors, and nasal spray delivery systems. Public-private partnerships enhance development initiatives.

• Pentazocine: Limited R&D investments focus on reformulations to reduce misuse and improve safety profiles.

Key Market Players and Their Financials

Company	Revenue from Naloxone (2022)	Revenue from Pentazocine (2022)	Notes
Viatris	~$600 million	N/A	Largest market share for naloxone
Hikma	~$300 million	N/A	Strong in generics, expanding formulations
Allergan (AbbVie)	N/A	N/A	Formerly produced Pentazocine; market share declining

What Are the Future Market Challenges and Opportunities?

Challenges

• Regulatory restrictions limiting OTC access to naloxone in certain markets.
• Price competition from generics reducing margins.
• Misinformation and stigma hindering broader distribution.

Opportunities

• Approval of long-acting and novel delivery systems for naloxone.
• Growing public health initiatives backing naloxone distribution.
• Potential reformulations of pentazocine to minimize abuse potential.

Key Takeaways

• The global market for naloxone is expanding rapidly, driven by overdose epidemics and regulatory shifts favoring wider access.
• Pentazocine's market remains niche; growth is constrained by prescriber preferences and regulatory controls.
• Investment focus is shifting towards innovative delivery systems for naloxone, with R&D targeting long-acting and user-friendly formulations.
• Patent expirations and subsequent generic entry pressure prices downward, but increased volume offsets margin compression.
• Regulatory and social barriers continue to influence overall market growth prospects.

Frequently Asked Questions

1. How does regulatory policy impact the naloxone market?

Regulatory policies facilitate or restrict OTC access. Countries expanding OTC availability see increased market penetration, leading to higher sales. Conversely, restrictions delay distribution and limit revenue growth.

2. What are the primary drivers for pentazocine demand?

Demand stems from hospitals and pain management clinics seeking opioid options. Its prescribing is affected by concerns over misuse and the availability of alternative analgesics, influencing growth stability.

3. Which countries lead in naloxone adoption?

The US, UK, and Australia dominate in naloxone market penetration due to robust public health efforts and supportive legislation.

4. How are pricing trends expected to evolve?

Pricing for naloxone is decreasing due to generic competition, but overall revenue remains strong due to volume increases. Pentazocine prices remain stable with minimal fluctuation.

5. What role do new formulations play in market growth?

Long-acting, nasal, and auto-injector formulations for naloxone increase ease of use, expand access points, and drive sales growth.

References

[1] MarketWatch. (2023). Naloxone market size and forecast.
[2] Grand View Research. (2022). Pentazocine Hydrochloride market report.
[3] U.S. Food and Drug Administration. (2019). Naloxone access and approvals.